238 related articles for article (PubMed ID: 28208086)
21. Spectrum of Autoimmune Bullous Diseases in Northern Greece. A 4-year Retrospective Study and Review of the Literature.
Patsatsi A; Lamprou F; Kokolios M; Stylianidou D; Trigoni A; Kalampalikis D; Sotiriadis D
Acta Dermatovenerol Croat; 2017 Oct; 25(3):195-201. PubMed ID: 29252171
[TBL] [Abstract][Full Text] [Related]
22. Skin-Related Quality of Life During Autoimmune Bullous Disease Course.
Hopkins ZH; Jimenez A; Taliercio VL; Clarke JT; Hansen CB; Hull CM; Rhoads JLW; Zone JJ; Sahni VN; Kean J; Secrest AM
JAMA Dermatol; 2023 Nov; 159(11):1185-1194. PubMed ID: 37703003
[TBL] [Abstract][Full Text] [Related]
23. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany.
Bertram F; Bröcker EB; Zillikens D; Schmidt E
J Dtsch Dermatol Ges; 2009 May; 7(5):434-40. PubMed ID: 19170813
[TBL] [Abstract][Full Text] [Related]
24. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
Atzori L; Deidda S; Aste N
G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.
Sadik CD; Rashid H; Hammers CM; Diercks GFH; Weidinger A; Beissert S; Schauer F; Fettiplace J; Thaçi D; Ngai Y; Nunn MA; Zillikens D; Horváth B
JAMA Dermatol; 2022 Jun; 158(6):641-649. PubMed ID: 35507334
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and quality of life in pemphigus patients.
Tee CT; Lee CS; Gunabalasingam P
Med J Malaysia; 2022 May; 77(3):324-330. PubMed ID: 35638489
[TBL] [Abstract][Full Text] [Related]
27. Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatoses.
Iwata H; Bieber K; Hirose M; Ludwig RJ
Curr Pharm Des; 2015; 21(18):2422-39. PubMed ID: 25777758
[TBL] [Abstract][Full Text] [Related]
28. Autoimmune bullous diseases in Austria.
Laimer M; Pohla-Gubo G; Kraus L; Nischler E; Bauer JW; Ahlgrimm-Siess V; Hintner H
Dermatol Clin; 2011 Oct; 29(4):691-8. PubMed ID: 21925021
[TBL] [Abstract][Full Text] [Related]
29. Validity and reliability of the Polish version of myasthenia gravis - Quality of life questionnaire - 15 item.
Rozmilowska I; Adamczyk-Sowa M; Pierzchala K; Czyzewski D
Neurol Neurochir Pol; 2017; 51(4):311-318. PubMed ID: 28579082
[TBL] [Abstract][Full Text] [Related]
30. Spectrum of autoimmune bullous diseases among children in Kuwait.
Nanda A; Lazarevic V; Rajy JM; Almasry IM; AlSabah H; AlLafi A
Pediatr Dermatol; 2021 Jan; 38(1):50-57. PubMed ID: 33043506
[TBL] [Abstract][Full Text] [Related]
31. Spectrum of Autoimmune Bullous Diseases in the Middle East: A 15-Year Review.
Haber R; Helou J; Habr C; Tomb R
Skinmed; 2017; 15(3):181-186. PubMed ID: 28705277
[TBL] [Abstract][Full Text] [Related]
32. Objective scoring systems for disease activity in autoimmune bullous disease.
Sebaratnam DF; Murrell DF
Dermatol Clin; 2011 Jul; 29(3):515-20, xi. PubMed ID: 21605820
[TBL] [Abstract][Full Text] [Related]
33. Clinical, demographic and immunopathological spectrum of subepidermal autoimmune bullous diseases at a tertiary center: A 1-year audit.
De D; Khullar G; Handa S; Saikia UN; Radotra BD; Saikia B; Minz RW
Indian J Dermatol Venereol Leprol; 2016; 82(3):358. PubMed ID: 27088957
[TBL] [Abstract][Full Text] [Related]
34. Sexual quality of life in patients with pemphigus: A case-control study.
Maione V; Bettolini L; Cozzi C; Bighetti S; Tomasi C; Calzavara-Pinton P
J Eur Acad Dermatol Venereol; 2024 Apr; 38(4):761-768. PubMed ID: 38071729
[TBL] [Abstract][Full Text] [Related]
35. The Role of Mast Cells in Autoimmune Bullous Dermatoses.
Yu X; Kasprick A; Hartmann K; Petersen F
Front Immunol; 2018; 9():386. PubMed ID: 29541076
[TBL] [Abstract][Full Text] [Related]
36. Management of autoimmune bullous diseases in France: a nationwide network of 30 centers.
Meyer N; Paul C; Joly P
Dermatol Clin; 2011 Oct; 29(4):659-62. PubMed ID: 21925014
[TBL] [Abstract][Full Text] [Related]
37. Incidence of pemphigoid diseases in Northern Germany in 2016 - first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases.
van Beek N; Weidinger A; Schneider SW; Kleinheinz A; Gläser R; Holtsche MM; von Georg A; Hammers CM; Hübner F; Lima AL; Gola D; Sadik CD; Zillikens D; Katalinic A; Schmidt E; König IR
J Eur Acad Dermatol Venereol; 2021 May; 35(5):1197-1202. PubMed ID: 33428263
[TBL] [Abstract][Full Text] [Related]
38. Retrospective Study on Autoimmune Blistering Disease in Paediatric Patients.
Kong YL; Lim YL; Chandran NS
Pediatr Dermatol; 2015; 32(6):845-52. PubMed ID: 26391853
[TBL] [Abstract][Full Text] [Related]
39. The Polish version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) - four-stage translation and validation.
Karbownik-Lewińska M; Lewiński A; McKenna S; Kokoszko A; Mucha S; Komorowski J; Krzyzanowska-Swiniarska B; Gryczyńska M; Sowiński J; Junik R; Meads D; Kołtowska-Häggström M
Endokrynol Pol; 2008; 59(5):374-84. PubMed ID: 18979446
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D status in patients with autoimmune bullous dermatoses: a meta-analysis.
Yang M; Wu H; Zhao M; Long H; Lu Q
J Dermatolog Treat; 2022 May; 33(3):1356-1367. PubMed ID: 32799714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
